A recent collaborative study has identified two promising single-domain antibodies (sdAbs) that may offer a therapeutic option against multiple subtypes of Venezuelan equine encephalitis virus (VEEV). The researchers, from the U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health’s Vaccine Research Center, U.S. Naval Research Laboratory, and the Frederick National Laboratory for Cancer Research, have published their findings in the Journal of Virology.
This article was originally published on MedicalXpress.com
